Thanks for the links, sox. I remember staring at the diagram for quite a while several months ago. Though I have a decent understanding of what's going on, I certainly haven't wrapped my arms around the downstream duration of action after Kevetrin dosing. It'd be great if there was a continuous infusion, escalating dose arm of a future Kevetrin study for patients with Port-A-Cath's or some other implanted long-term central venous access. More may not be better but a continuous relatively low-dose infusion might do wonders.

I am excited about the planned upcoming ulcerative proctitis trial. In that ulcerative proctitis represents 25-30% of patients with ulcerative colitis, it's a great market with an unmet need. Moving forward with this trial also suggests that they are seeing good things with B-OM.

www.badgut.org/information-centre/a-z-digestive-topics/ulcerative-proctitis/